SCHEMBL5533199

SCHEMBL5533199

NC(=O)COc1cc(Cl)c(Cl)cc1Cl

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.62
TDP1 Q9NUW8 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
TSHR P16473 1/20 0.54
ALDH1A1 P00352 5/20 0.54
FKBP1A P62942 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
RAB9A P51151 3/20 0.51
NPC1 O15118 2/20 0.51
KDM4E B2RXH2 2/20 0.51
KMT2A Q03164 2/20 0.51
HPGD P15428 1/20 0.51
MAPK1 P28482 1/20 0.50
MAPT P10636 2/20 0.49
HTT P42858 2/20 0.49
NPSR1 Q6W5P4 1/20 0.47
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13744823 0.85 KMT2A (0.52) LMNATDP1L3MBTL1TSHRALDH1A1
2,4,5-Trichlorophenoxyacetic Acid SCHEMBL117704 0.82 TDP1 (0.65) LMNATDP1L3MBTL1TSHRALDH1A1
2,4,5-Trichlorophenoxyacetic Acid SCHEMBL30445640 0.82 TDP1 (0.65) LMNATDP1L3MBTL1TSHRALDH1A1
2,4,5-Trichlorophenoxyacetic Acid SCHEMBL4864791 0.82 TDP1 (0.65) LMNATDP1L3MBTL1TSHRALDH1A1
SCHEMBL3165661 0.82 LMNA (0.65) LMNATDP1L3MBTL1TSHRALDH1A1
SCHEMBL11642798 0.82 LMNA (0.65) LMNATDP1L3MBTL1TSHRALDH1A1
2,4,5-Trichlorophenoxyacetic Acid SCHEMBL29525126 0.82 TDP1 (0.65) LMNATDP1L3MBTL1TSHRALDH1A1
SCHEMBL1117054 0.81 LMNA (0.50) LMNATDP1L3MBTL1TSHRALDH1A1
SCHEMBL15040607 0.80 ALDH1A1 (0.52) LMNAL3MBTL1ALDH1A1SMN1; SMN2RAB9A
2,4,5-Trichlorophenoxyacetic Acid SCHEMBL4586268 0.80 TDP1 (0.62) LMNATDP1L3MBTL1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 LMNA 2932/4885TDP1 1807/4885L3MBTL1 3309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.